このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Multimodal Assessment of Remodeling and Stratification in Heart Failure (MARS-HF)

2026年11月10日 更新者:Shandong Provincial Hospital

Artificial Intelligence-Enhanced Multimodal Cardiovascular Phenotyping for Cardiac Remodeling and Risk Stratification in Ischemic and Nonischemic Acute and Chronic Heart Failure: A Prospective, Multicenter, Observational Cohort Study

Heart failure is a common condition in which the heart cannot pump blood effectively. It can be caused by reduced blood supply to the heart (ischemic) or by other causes (nonischemic), and it may begin suddenly (acute) or last for a long time (chronic). Heart failure can lead to changes in the heart's structure and function, called cardiac remodeling, and to different risks of hospitalization or death.

This is a prospective, multicenter, observational study. It will enroll adults with acute or chronic heart failure, including both ischemic and nonischemic types. Participants will receive their usual medical care and will undergo multimodal assessments. These may include cardiac magnetic resonance imaging, echocardiography, electrocardiography, blood tests, and computed tomography, including high-resolution coronary CT or photon-counting CT when available. Data on heart structure, function, blood flow, tissue characteristics, and clinical outcomes will be collected during follow-up.

The main goals are to better understand cardiac remodeling in different types of heart failure and to find out whether combining information from different tests can improve risk stratification. Advanced statistical methods and artificial intelligence will be explored as part of the analysis, but artificial intelligence is not the main focus; the study aims to integrate all data sources in a balanced way. No new drug or device will be tested. The results may help doctors improve how they evaluate and monitor patients with heart failure.

調査の概要

状態

募集

条件

詳細な説明

Detailed Description

Heart failure is a heterogeneous clinical syndrome in which the heart cannot pump blood effectively. Patients with heart failure differ widely in cause, presentation, cardiac structure and function, and prognosis. Ischemic and nonischemic heart failure, as well as acute and chronic heart failure, may have different patterns of cardiac remodeling and different risks of adverse events. Standard clinical assessment, laboratory tests, and single imaging methods provide important but incomplete information. Combining multiple sources of data may give a more complete picture of the disease and may improve risk stratification.

This is a prospective, multicenter, observational cohort study. It will enroll adults with acute or chronic heart failure, including both ischemic and nonischemic causes. Participants will receive their usual medical care. No experimental drug, device, or treatment will be administered. Treatment decisions will remain at the discretion of the treating physicians.

The study will collect clinical, electrocardiographic, laboratory, and multimodal imaging data using a standardized protocol. Multimodal assessments may include cardiac magnetic resonance imaging, echocardiography, electrocardiography, blood tests, and computed tomography. Cardiac magnetic resonance parameters may include late gadolinium enhancement, extracellular volume, T1 mapping, T2 mapping, strain, cardiac diffusion tensor imaging, four-dimensional flow, and stress perfusion. Computed tomography may include CT angiography and, when available, photon-counting CT for high-resolution coronary imaging. Echocardiography may include chamber size, systolic and diastolic function, strain, and valve assessment. Laboratory tests may include biomarkers such as natriuretic peptides, troponin, renal function, and other clinically relevant markers.

The main objectives are:

To characterize cardiac remodeling across ischemic, nonischemic, acute, and chronic heart failure using integrated multimodal data.

To evaluate the associations between multimodal markers and clinical outcomes.

To develop and validate risk stratification models that combine information from different modalities in a balanced way.

To compare the incremental value of advanced imaging and clinical parameters beyond conventional assessment.

To explore artificial intelligence and other advanced analytical methods as part of the analysis, although artificial intelligence is not the main focus of the study.

Participants will be followed for [e.g., 12 to 24 months] according to the study protocol. Data will be collected at baseline and at prespecified follow-up visits. Clinical outcomes may include death, heart failure hospitalization, major adverse cardiovascular events, arrhythmia, changes in symptoms and functional status, and changes in cardiac structure and function. Outcome information will be obtained from clinic visits, medical records, telephone contact, and registries where available.

Statistical analysis will include descriptive analyses, regression models, survival analyses, and advanced modeling methods. Artificial intelligence and machine learning will be explored as one of several analytical approaches, alongside conventional statistical methods. Models will be internally validated, and external validation will be performed if feasible. Missing data will be handled using appropriate methods, and subgroup analyses will be performed for ischemic versus nonischemic and acute versus chronic heart failure.

This study may improve the understanding of cardiac remodeling in different types of heart failure and may help identify patients at higher risk. The results may support the development of more comprehensive and balanced multimodal assessment strategies and may inform future clinical studies. The study will be conducted in accordance with ethical principles and applicable regulations. Institutional review board or ethics committee approval will be obtained, and informed consent will be required from all participants.

研究の種類

観察的

入学 (推定)

2000

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Wenxian Wang, Dr
  • 電話番号:8617705414294
  • メール:wwx990511@163.com

研究場所

    • Liaoning
      • Shenyang、Liaoning、中国
        • 募集
        • The First Affiliated Hospital of China Medical University
    • Shandong
      • Jinan、Shandong、中国
        • 募集
        • Shandong Provincial Hospital Affiliated to Shandong First Medical University
        • コンタクト:
      • Jinan、Shandong、中国
        • 募集
        • Jinan central hospital
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

サンプリング方法

確率サンプル

調査対象母集団

Patients with DCM, HCM, myocarditis, or ischemic and non-ischemic chronic and acute heart failure meeting the composite clinical diagnosis

説明

Dilated Cardiomyopathy Inclusion criteria: Diagnosed dilated cardiomyopathy (DCM) according to the World Health Organization / International Society and Federation of Cardiology (WHO/ISFC) criteria, characterized by elevated body surface area-indexed left ventricular end-diastolic volume and left ventricular ejection fraction (LVEF) below published age- and sex-specific reference values.

Exclusion criteria: Severe coronary artery disease (CAD, defined as >50% stenosis of a major coronary artery), infiltrative cardiomyopathy, arrhythmogenic

HCM Inclusion criteria: The diagnosis of hypertrophic cardiomyopathy is independently made by clinicians according to current guidelines, based on imaging examinations including CMR, electrocardiography, family history and genetic testing (if available). Inclusion criterion: left ventricular wall thickness ≥13 mm in ≥1 myocardial segment on CMR.

Exclusion criteria: Apical hypertrophic myocardial infarction, any contraindications to CMR, adenosine or gadolinium (Gd)-based contrast agents, systemic hypertension, severe valvular disease, infiltrative cardiomyopathy, prior myocardial infarction or coronary intervention.

Chronic Heart Failure Inclusion criteria: age ≥18 years; established clinical diagnosis of chronic heart failure for at least 3 months based on current guideline criteria; NYHA class I-IV; LVEF assessed within 12 months by echocardiography, CMR, or other validated imaging, meeting HFrEF (LVEF ≤40%), HFmrEF (LVEF 41-49%), or HFpEF (LVEF ≥50%); for HFpEF, at least one supportive finding documented within 12 months (elevated NT-proBNP >125 pg/mL or BNP >35 pg/mL, structural heart disease such as left atrial enlargement, left ventricular hypertrophy, or diastolic dysfunction, or prior heart failure hospitalization); stable clinical condition with no change in NYHA class or heart failure-specific therapy within 7 days before enrollment; receiving guideline-directed medical therapy at a stable dose for at least 4 weeks unless contraindicated or not tolerated; ability to provide written informed consent Exclusion criteria:General: age <18 years; pregnant or breastfeeding; women of childbearing potential unwilling to use effective contraception during the study; life expectancy <12 months due to non-cardiac disease; concurrent acute coronary syndrome at screening (typical chest pain with troponin above 99th percentile and electrocardiographic changes suggestive of ischemia); history of cardiac transplantation or current ventricular assist device; prior solid organ transplantation; systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg at screening; estimated glomerular filtration rate <30 mL/min/1.73 m²; renal replacement therapy or ultrafiltration before enrollment; severe hepatic impairment (Child-Pugh class C); known or suspected non-cardiac cirrhosis; active malignancy or current treatment for malignancy that may affect participation or outcomes; any condition that may interfere with compliance or compromise data quality. CMR-specific: any absolute contraindication to MRI including non-MR-conditional pacemaker or implantable cardioverter-defibrillator, intracranial aneurysm clips, metallic intraocular foreign body, cochlear/otological/ear implant, neurostimulator, or non-MR-conditional monitoring/support devices; severe claustrophobia not manageable with preparation or mild sedation; contraindication to gadolinium-based contrast agents including previous anaphylactic reaction, eGFR <30 mL/min/1.73 m², known nephrogenic systemic fibrosis, or pregnancy; inability to lie flat or hold breath sufficiently for image acquisition; clinically unstable condition precluding safe MRI. Stress perfusion-specific: previous anaphylactic reaction to adenosine, regadenoson, or dobutamine; severe obstructive airways disease or mild-to-moderate disease with contraindication to adenosine/regadenoson; high-degree atrioventricular block or symptomatic bradycardia (<40 beats per minute) without functioning pacemaker; symptomatic severe or critical aortic stenosis; known left ventricular thrombus; uncontrolled arterial hypertension or uncontrolled atrial fibrillation during imaging; acute coronary or aortic syndrome within 7 days before imaging; concomitant theophylline, dipyridamole, or caffeine within 6-12 hours before stress perfusion imaging.

Acute decompensated heart failure Inclusion criteria: male or female adults aged ≥18 years; current hospitalization or unscheduled clinic/emergency department visit for a primary diagnosis of acute decompensated heart failure (de novo or decompensation of chronic heart failure) regardless of LVEF category (HFrEF, HFmrEF, or HFpEF); at least one clinical sign of volume overload (peripheral edema score ≥2, pulmonary congestion or pleural effusion on chest X-ray or ultrasound, ascites on ultrasound, or elevated jugular venous pressure); elevated natriuretic peptides (NT-proBNP >1000 pg/mL or BNP >250 pg/mL); receiving or anticipated to receive intravenous diuretic therapy during the index hospitalization or acute care episode; for HFpEF, diagnosis supported by structural heart disease and/or diastolic dysfunction plus elevated natriuretic peptides; ability to provide written informed consent or consent from a legally authorized representative if temporarily unable. Exclusion criteria:General: age <18 years; pregnant or breastfeeding; women of childbearing potential unwilling to use effective contraception during the study; life expectancy <12 months due to non-cardiac disease; concurrent acute coronary syndrome at screening (typical chest pain with troponin above 99th percentile and electrocardiographic changes suggestive of ischemia); history of cardiac transplantation or current ventricular assist device; prior solid organ transplantation; systolic blood pressure <90 mmHg or mean arterial pressure <65 mmHg at screening; estimated glomerular filtration rate <30 mL/min/1.73 m²; renal replacement therapy or ultrafiltration before enrollment; severe hepatic impairment (Child-Pugh class C); known or suspected non-cardiac cirrhosis; active malignancy or current treatment for malignancy that may affect participation or outcomes; any condition that may interfere with compliance or compromise data quality. CMR-specific: any absolute contraindication to MRI including non-MR-conditional pacemaker or implantable cardioverter-defibrillator, intracranial aneurysm clips, metallic intraocular foreign body, cochlear/otological/ear implant, neurostimulator, or non-MR-conditional monitoring/support devices; severe claustrophobia not manageable with preparation or mild sedation; contraindication to gadolinium-based contrast agents including previous anaphylactic reaction, eGFR <30 mL/min/1.73 m², known nephrogenic systemic fibrosis, or pregnancy; inability to lie flat or hold breath sufficiently for image acquisition; clinically unstable condition precluding safe MRI. Stress perfusion-specific: previous anaphylactic reaction to adenosine, regadenoson, or dobutamine; severe obstructive airways disease or mild-to-moderate disease with contraindication to adenosine/regadenoson; high-degree atrioventricular block or symptomatic bradycardia (<40 beats per minute) without functioning pacemaker; symptomatic severe or critical aortic stenosis; known left ventricular thrombus; uncontrolled arterial hypertension or uncontrolled atrial fibrillation during imaging; acute coronary or aortic syndrome within 7 days before imaging; concomitant theophylline, dipyridamole, or caffeine within 6-12 hours before stress perfusion imaging.

myocarditis Inclusion Criteria: Male or female adults aged ≥18 years; diagnosis of myocarditis confirmed by at least one of the following: (a) cardiac magnetic resonance fulfilling the modified Lake Louise Criteria (at least one T2-based criterion for myocardial edema AND at least one T1-based criterion including native T1 mapping, extracellular volume, or late gadolinium enhancement in a non-ischemic distribution), OR (b) endomyocardial biopsy demonstrating histologic, immunologic, and immunohistochemical evidence of myocardial inflammation; OR (c) in patients with high clinical pretest probability, a combination of at least one clinical presentation (acute chest pain, dyspnea, palpitations, arrhythmia, syncope, or unexplained cardiogenic shock) AND at least one diagnostic finding (elevated cardiac troponin, ECG changes suggestive of myocardial injury, or echocardiographic evidence of new regional or global wall motion abnormality) AND CMR findings consistent with myocardial inflammation; time from symptom onset classified as acute (<4 weeks), subacute (4-12 weeks), or chronic (>3 months); for chronic myocarditis, persistent or recurrent symptoms or imaging evidence of ongoing myocardial inflammation for >3 months from initial onset; receiving standard clinical care, including guideline-directed medical therapy for heart failure when applicable; ability to provide written informed consent prior to any study-related assessment, or consent from a legally authorized representative if temporarily unable.

CAD: were the following: (1) age > 18 years; (2) CAD diagnosed according to current guidelines [10, 11]-(a) atleast 70% stenosis in one or more coronary arteries or > 50% stenosis of the left main stem in percutaneous coronary intervention (PCI) or computed tomography angiography (CTA); (b) history of severe angina or myocardial infarction (MI); (c) previous revascularization history, including surgical coronary artery bypass grafting (CABG).The exclusion criteria were the following: (1) definite non-ischemic heart disease; (2)acute MI; (3) any contraindication to CMR.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
Patient group

Participants enrolled who meet the diagnostic criteria according to clinical guidelines and the inclusion and exclusion criteria

Healthy volunteers

Healthy volunteer group matched with the patient group for age and sex

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Heart failure-related composite endpoint
時間枠:At 3, 6, 12, 24, 36 and 48 months after CMR examination

The prespecified primary endpoint was a composite of heart failure (HF) events, including HF-related death, unplanned HF hospitalization, or cardiac transplantation. Death was attributed to HF if progressive worsening of HF symptoms and signs occurred before death. HF hospitalization was defined as admission due to new or worsening HF symptoms and signs requiring intensified HF-specific therapy.

At 3, 6, 12, 24, 36 and 48 months after CMR examination

二次結果の測定

結果測定
メジャーの説明
時間枠
Sudden Cardiac Death (SCD)-related endpoint
時間枠:At 3, 6, 12, 24, 36 and 48 months after CMR examination

The prespecified primary endpoint of this study was a composite of SCD-related events, including SCD, appropriate ICD shock, and resuscitated cardiac arrest.

At 3, 6, 12, 24, 36 and 48 months after CMR examination

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年12月1日

一次修了 (推定)

2029年9月10日

研究の完了 (推定)

2030年9月10日

試験登録日

最初に提出

2026年11月10日

QC基準を満たした最初の提出物

2026年11月10日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • SWYX:NO.2025-524

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。